Methods and compositions for treating mammalian nerve tissue injuries
To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury.
1. A method for treating an injury to nerve tissue of a mammalian patient, the method comprising administering an effective amount of a composition comprising at least one polyalkylene glycol selected from the group consisting of polymethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers and mixtures thereof to the patient so that the polyalkylene glycol is delivered via the patient's vascular system to the site of the injured nerve tissue, wherein the polyalkylene glycol is at least 30% by weight in the composition.
2. The method of claim 1 wherein said polyalkylene glycol comprises polyethylene glycol.
3. The method of claim 1 , wherein said polyalkylene glycol is in a pharmaceutically acceptable carrier.
4. The method of claim 3 , wherein said carrier is water.
5. The method of claim 1 , wherein said polyalkylene glycol has a molecular weight of about 400 daltons to about 3500 daltons.
6. The method of claim 1 , wherein the administering of said effective amount of said polyalkylene glycol includes injecting said polyalkylene glycol into a vascular system of the patient.
7. The method of claim 1 , wherein the administering of said effective amount of said polyalkylene glycol includes injecting said polyalkylene glycol subcutaneously into the patient.
8. The method of claim 1 , wherein the administering of said effective amount of said polyalkylene glycol includes injecting said polyalkylene glycol intraperitoneally into the patient.
9. The method of claim 1 , wherein the injured nerve tissue is spinal cord tissue.
10. The method of claim 1 , wherein the injured nerve tissue is peripheral nerve tissue.
11. The method of claim 1 , wherein delivery by way of the patient's vascular system is effected using a technique selected from the group consisting of intravascular, intramuscular, subcutaneous, and intraperitoneal injection.
12. The method of claim 11 , wherein the intravascular injection is an intravenous injection.
13. The method of claim 1 , wherein the injury comprises an injury selected from the group consisting of a mechanical injury, a biochemical injury, and an ischemic injury.
14. The method of claim 1 , wherein said polyalkylene glycol has a molecular weight of about 200 daltons to about 25,000 daltons.
15. The method of claim 1 , wherein said polyalkylene glycol has a molecular weight of about 1,500 daltons to about 4,000 daltons.
16. The method of claim 1 , wherein said composition comprising at least one polyalkylene glycol further comprises a potassium channel blocker.
17. The method of claim 16 wherein said potassium channel blocker comprises 4-aminopyridine.
18. The method of claim 1 , further comprising administering a potassium channel blocker before, during, or after administering said composition comprising at least one polyalkylene glycol.
19. The method of claim 18 , wherein said potassium channel blocker comprises 4-aminopyridine.
20. A method for treating an injury to nerve tissue of a mammalian patient, the method comprising administering an effective amount of a composition comprising at least one polyalkylene glycol selected from the group consisting of polymethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers and mixtures thereof to the patient so that the polyalkylene glycol is delivered via the patient's vascular system to the site of the injured nerve tissue, wherein the polyalkylene glycol is about 15% to about 50% by weight in the composition.